Comparative transcriptomic and proteomic signature of lung alveolar macrophages reveals the integrin CD11b as a regulatory hub during pneumococcal pneumonia infection

Front Immunol. 2023 Sep 18:14:1227191. doi: 10.3389/fimmu.2023.1227191. eCollection 2023.

Abstract

Introduction: Streptococcus pneumoniae is one of the main causes of community-acquired infections in the lung alveoli in children and the elderly. Alveolar macrophages (AM) patrol alveoli in homeostasis and under infectious conditions. However, the molecular adaptations of AM upon infections with Streptococcus pneumoniae are incompletely resolved.

Methods: We used a comparative transcriptomic and proteomic approach to provide novel insights into the cellular mechanism that changes the molecular signature of AM during lung infections. Using a tandem mass spectrometry approach to murine cell-sorted AM, we revealed significant proteomic changes upon lung infection with Streptococcus pneumoniae.

Results: AM showed a strong neutrophil-associated proteomic signature, such as expression of CD11b, MPO, neutrophil gelatinases, and elastases, which was associated with phagocytosis of recruited neutrophils. Transcriptomic analysis indicated intrinsic expression of CD11b by AM. Moreover, comparative transcriptomic and proteomic profiling identified CD11b as the central molecular hub in AM, which influenced neutrophil recruitment, activation, and migration.

Discussion: In conclusion, our study provides novel insights into the intrinsic molecular adaptations of AM upon lung infection with Streptococcus pneumoniae and reveals profound alterations critical for effective antimicrobial immunity.

Keywords: alveolar macrophage; bioinformatics; infection; proteomics; transcriptomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD11b Antigen*
  • Integrins
  • Lung
  • Macrophages, Alveolar
  • Mice
  • Pneumonia, Pneumococcal*
  • Proteomics
  • Streptococcus pneumoniae
  • Transcriptome

Substances

  • Integrins
  • CD11b Antigen

Grants and funding

DRE and OS received funding from the German Research Foundation: FOR5427 SP1 (OS); FOR5427 SP4 (DRE); EN984/15-1 and 16-1 (DRE); TR296 P09 (DRE); TR332 A3 and Z1 (DRE); INST 20876/486-1.